[MO30] Mini-Oral Session 30　Hematologic Malignancies
【E】

[MO30-1] Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients

^○Akinao Okamoto¹, Fujigaki Hidetsugu², Iriyama Chisako¹, Goto Naoe¹, Yamamoto Hideyuki¹, Mihara Keichiro³, Inaguma Yoko⁴, Miura Yasuo⁵, Furukawa Katsuya⁶, Yamamoto Yukiya⁷, Akatsuka Yoshiki⁸, Kasahara Senji⁹, Miyao Kotaro¹⁰, Masataka Okamoto¹, Kuniaki Saito², Akihiho Tomita¹ (1.Department of Hematology, Fujita Health University School of Medicine, 2.Department of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Sciences, 3.International Center for Cell and Gene Therapy, Fujita Health University School of Medicine, 4.Department of Clinical General Medicine, Fujita Health University School of Medicine, 5.Department of Transfusion Medicine and Cell Therapy, Fujita Health University School of Medicine, 6.Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 7.Department of Biochemical and Sciences, Chubu University, Kasugai, 8.Department of Immunology, Nagoya University Graduate School of Medicine, 9.Department of Hematology, Gifu Municipal Hospital, 10.Department of Hematology and Oncology, Anjo Kosei Hospital)